Merck & Co., Inc. (MRK) Set to Post Quarterly Earnings on Thursday

Merck & Co., Inc. (NYSE:MRK) is anticipated to release its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Merck & Co., Inc. to post earnings of $2.09 per share and revenue of $17.31 billion for the quarter. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Investors may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 9:00 AM ET.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the prior year, the company posted $2.13 earnings per share. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. On average, analysts expect Merck & Co., Inc. to post $2.64 EPS for the current fiscal year and $9.26 EPS for the next fiscal year.

Merck & Co., Inc. Price Performance

MRK stock opened at $140.36 on Tuesday. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a 12 month low of $82.01 and a 12 month high of $156.92. The firm has a market cap of $346.28 billion, a P/E ratio of 112.29, a P/E/G ratio of 6.74 and a beta of 0.21. The company’s 50-day moving average price is $146.69 and its two-hundred day moving average price is $125.84.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th were issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend was Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 272.00%.

Wall Street Analyst Weigh In

Several analysts recently issued reports on MRK shares. HSBC increased their price target on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Wells Fargo & Company lifted their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Berenberg Bank boosted their price objective on shares of Merck & Co., Inc. from $127.00 to $137.00 and gave the company a “hold” rating in a research report on Friday, September 11th. UBS Group upped their target price on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Finally, Citigroup upped their target price on Merck & Co., Inc. from $125.00 to $145.00 and gave the stock a “neutral” rating in a research note on Monday, October 12th. Seventeen investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $153.12.

Insider Activity

In other news, EVP David Williams sold 52,847 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the sale, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the sale, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. This trade represents a 24.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 228,238 shares of company stock valued at $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and partner Daiichi Sankyo reported positive Phase 3 results for sacituzumab tirumotecan (Sac-TMT) in certain patients with advanced or recurrent endometrial cancer. The treatment reduced the risk of death by 32% and the risk of disease progression or death by 41% versus chemotherapy; median overall survival was 19 months compared with 12.1 months. An FDA decision is expected by June 2027. Sac-TMT Phase 3 results
• Positive Sentiment: KEYTRUDA monotherapy reduced the risk of disease progression or death by 43% in a specified group of patients with mismatch repair-deficient endometrial cancer, reinforcing the drug’s oncology franchise and potential for additional indications. KEYTRUDA endometrial cancer results
• Positive Sentiment: Barclays raised its MRK price target to $180 from $150 and maintained an overweight rating. Another valuation update lifted fair value to $159.76 from $155.68, citing Merck’s oncology pipeline and cancer-vaccine partnership. Barclays price-target increase
• Neutral Sentiment: Merck and Moderna’s personalized melanoma vaccine reduced recurrence or death by 42% when added to KEYTRUDA in a Phase 3 trial. However, the result was below some elevated investor expectations, and overall-survival data remain immature. Merck’s October 29 earnings call may provide details on regulatory filings, launch economics and the vaccine’s role in offsetting future Keytruda losses.
• Negative Sentiment: Investors remain focused on Keytruda’s compound-patent expiration in December 2028. Upcoming results must show that newer products—including Winrevair, Keytruda QLEX and other pipeline assets—can support management’s “shallow dip” outlook.
• Negative Sentiment: New U.S. Treasury restrictions on certain U.S. collaborations and investments involving Chinese biotech companies could limit Merck’s access to partnerships, research and potential cancer-drug candidates from China. China biotech restrictions and Merck

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.